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Yeast vacuole fusion requires palmitoylated Vac8.
We previously showed that Vac8 acylation occurs early
in the fusion reaction, is blocked by antibodies against
Sec18 (yeast N-ethylmaleimide-sensitive fusion pro-
tein (NSF)), and is mediated by the R-SNARE Ykt6.
Here we analyzed the regulation of this reaction on
purified vacuoles. We show that Vac8 acylation is re-
stricted to a narrow time window, is independent of
ATP hydrolysis by Sec18, and is stimulated by the ion
chelator EDTA. Analysis of vacuole protein complexes
indicated that Ykt6 is part of a complex distinct from
the second R-SNARE, Nyv1. We speculate that during
vacuole fusion, Nyv1 is the classical R-SNARE,
whereas the Ykt6-containing complex has a novel func-
tion in Vac8 palmitoylation.
The post-translational modification of a protein can change
its conformation, subcellular localization, and function. Thus,
such highly consequent alterations must be tightly controlled
in time and space. Protein palmitoylation, or thiol (S)-acyla-
tion, is a reversible lipid modification, defined as the transfer of
an activated fatty acid, such as palmitoyl coenzyme A (Pal-
CoA),1 to a cysteine residue via a thioester linkage (reviewed in
Refs. 1 and 2). In this way, a cytosolic protein can be stably
anchored to membranes, an association that is made reversible
by thioesterases (2, 3).
Protein palmitoylation is involved in various viral and intra-
cellular fusion reactions, including synaptic vesicle fusion and
the homotypic fusion of yeast vacuoles (3–5). The latter re-
quires palmitoylation of the vacuolar protein Vac8 (6–8). Vac8
consists of three domains: (i) a myristoylated N-terminal Src
homology 4 domain with three cysteines that can be palmitoy-
lated, (ii) a long armadillo repeat, and (iii) a C-terminal aspar-
agine-rich stretch. Besides fusion, Vac8 is required for vacuole
inheritance, the maintenance of nucleus-vacuole junctions, and
the cytosol-to-vacuole transport of the aminopeptidase I, Ape1
(5, 6, 9–13).
Recently, we found that the R-SNARE (arginine-soluble NSF
attachment protein (SNAP) receptor) Ykt6 mediates Vac8 acy-
lation (14). Ykt6 is a ubiquitous SNARE found on multiple
membranes of the secretory and endocytic pathways (15–20).
Purified Ykt6 is sufficient to promote the transfer of Pal-CoA to
Vac8 (14). On yeast vacuoles, Ykt6 was found in association
with the glutamine (Q)-SNAREs Vam3, Vam7, and Vti1, the
R-SNARE Nyv1, and the AAA-ATPase Sec18 and its co-factor
Sec17 (yeast NSF/-SNAP), indicating that that all these pro-
teins form one complex, the cis-SNARE complex (16), which is
the putative result of a previous round of fusion (21). Vac8 is
also found in this complex (8), proximal to Ykt6 (14).
Fusion of isolated vacuoles is initiated when Sec18/17 disas-
semble the cis-SNARE complex in an ATP hydrolysis-depend-
ent manner (22, 23). This priming reaction allows the vacuolar
SNAREs to interact in trans (docking), which leads to lipid
mixing. We previously observed that priming and Vac8 palmi-
toylation occur simultaneously. Since both reactions were also
sensitive to antibodies against Sec18, we speculated that Vac8
acylation might be dependent on the priming reaction (8). How-
ever, the situation turned out to be more complicated, since
antibodies to Sec17, which also inhibit priming, do not affect
Vac8 acylation (14). We therefore proposed that, at the onset of
in vitro vacuole fusion, two Sec18-dependent reactions are trig-
gered: (a) together with Sec17, Sec18 mediates priming; and (b)
in a reaction independent (or upstream) of Sec17, Sec18 regu-
lates Vac8 acylation (14). The fact that all proteins involved in
these two reactions are part of, or associated to, the cis-SNARE
complex suggested to us that Vac8 acylation is a regulated
event dependent on specific components of a SNARE subcom-
plex. With this study we have characterized the regulation of
Vac8 palmitoylation during in vitro vacuole fusion and the
composition of vacuolar SNARE complexes in more detail.
EXPERIMENTAL PROCEDURES
Biochemical Reagents and Antibodies—[9,10-3H]Palmitic acid (50
Ci/mmol) was obtained from Hartmann Analytic (Braunschweig, Ger-
many). [3H]Pal-CoA was synthesized with [3H]palmitate and acyl-CoA
synthetase as described (24). All other biochemical reagents were pur-
chased from Sigma or Roth (Karlsruhe, Germany), unless indicated. All
reagents added to vacuoles were prepared in, or dialyzed into, PS buffer
(10 mM PIPES/KOH, pH 6.8, 200 mM sorbitol) unless indicated other-
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wise. Antibodies used were anti-hemagglutinin epitope (HA) mono-
clonal antibody (BabCO) and rabbit polyclonal antibodies against
Vam3, Nyv1, Vti1, Vam7, Ykt6, Sec17 (14, 25), and His-tagged GFP
(this study). Unless indicated, Nyv1-HA was detected with anti-HA
antibody. Antibodies to GFP were raised in New Zealand White rabbits
and affinity-purified as described (14) using CNBr-Sepharose (Amer-
sham Biosciences) immobilized pure protein. Preparations of IgGs and
affinity-purified antibodies were as described (26).
Yeast Strains and Molecular Biology—Saccharomyces cerevisiae
strains are listed in Table I. Yeast were cultured in yeast extract-
peptone-glucose. Nyv1 was C-terminally tagged with 6xHA by trans-
formation of a PCR fragment containing the tag and a TRP1 marker
into BJ3505 (CUY001) (27). Construction of the yeast strain CUY1250
containing internally GFP-tagged Ykt6 was as follows. DKY6281
(CUY002) was transformed with pRS416-YKT6pr-YKT6WT (47), and
endogenous YKT6 was deleted by replacement of the open reading
frame with the KANMX4 selection marker (28); the resulting strain was
unable to grow on synthetic medium containing 5-fluoroorotic acid,
confirming the ykt6 deletion. This strain was then transformed with the
plasmid pRS423-YKT6pr-GFPintYKT6 (47), and loss of pRS416-
YKT6pr-YKT6WT was induced by growth on 5-fluoroorotic acid. For
N-terminal tagging of Vam3 with glutathione S-transferase (GST), the
genomic VAM3 open reading frame without start codon was PCR-
amplified and inserted into the GST-containing vector pGEX4T-3 (Am-
ersham Biosciences). The newGST-VAM3 open reading frame was then
amplified by PCR and inserted into the yeast integrative vector pRS406
(29) containing the NOP1 promoter. The plasmid pRS406-NOP1pr-
GST-VAM3 was linearized in the URA3 marker and transformed into
BJ3505 vam3 (CUY010) and DKY6281 vam3 (CUY012) (25). Subse-
quent sequencing revealed that the Vam3 sequence has the point mu-
tation K96E, affecting a non-conserved residue in helix C of the N-
terminal extension. This does not affect the functionality of the protein,
as detailed under “Results.”
Recombinant Proteins—Purifications of Vac8-GST, His6-Sec18
E350Q, and His6-Sec18 from Escherichia coli were as described (8, 30).
His-tagged GFP, used for antibody production and affinity purification,
was expressed from the plasmid pET15b-eGFP (kindly provided by W.
Nickel, Biochemie-Zentrum der Universita¨t Heidelberg) and purified
from E. coli.
In Vitro Palmitoylation—BJ3505 vacuoles were incubated under fu-
sion conditions at 26 °C. Incubation times and time of [3H]Pal-CoA or
[3H]palmitate addition varied between experiments, as indicated in the
figure legends (Fig. 1 and 2). Where indicated Vac8-GST (15 g) was
added. Vacuoles were pelleted (10 min, 12,000  g), resuspended in PK
buffer (20 mM PIPES/KOH, pH 6.8, 120 mM KCl) containing 0.5 prote-
ase inhibitor mixture (1 protease inhibitor mixture  7.5 M Pefabloc
SC, 7.5 ng/ml leupeptin, 3.75 M o-phenanthroline, and 37.5 ng/ml pep-
statin (31)), and pelleted again. Vacuoles were resuspended in SDS sam-
ple buffer without 2-mercaptoethanol and analyzed by SDS-PAGE and
fluorography.
For extract preparation, membranes from a 200-l reaction (as de-
scribed above but without the addition of radioactive palmitate) were
solubilized in 100 l of Triton buffer (0.25% Triton X-100, 120 mM KCl,
20 mM PIPES/KOH pH 6.8, 1 protease inhibitor mixture) and incu-
bated for 1 h at 4 °C with agitation. Insoluble material was removed by
centrifugation (15 min, 20,000  g, 4 °C), and the supernatant (10 l,
about 5 g of vacuoles) was incubated with [3H]Pal-CoA in a total
volume of 100 l (adjusted with PK buffer) at 26 °C. Proteins were
precipitated with trichloroacetic acid (13% v/v) and acetone and ana-
lyzed by SDS-PAGE and fluorography.
Vacuole Isolation and in Vitro Fusion—Vacuoles were isolated from
the yeast strains BJ3505 (pep4 prb1) and DKY6281 (pho8) by
DEAE-dextran lysis and Ficoll gradient centrifugation. Fusion between
these vacuoles was measured by a biochemical complementation assay
as described (31). Briefly, 2–3 g each of pep4 and pho8 vacuoles
were incubated together at 26 °C in 30 l of PS buffer containing
protease inhibitor mixture (0.02/30 l), reaction salts (0.5 mM MgCl2,
0.5 mM MnCl2, 125 mM KCl), and CoA (10 M) in the presence or
absence of an ATP-regenerating system (0.5 mM ATP, 40 mM creatine
phosphate, 0.1 mg/ml creatine kinase). A colorimetric substrate, p-
nitrophenyl phosphate, for alkaline phosphatase was added to deter-
gent-solubilized reactions, and the absorbance at 400 nm was meas-
ured. One unit of fusion activity is defined as the production of 1 mol
of p-nitrophenol/min/g pep4 vacuoles.
Where indicated, reactions also contained cytosol (0.5 mg/ml (30)),
His6-Sec18 (200 ng/ml (30)), microcystin-LR (MCLR; 10 M; Alexis
Biochemicals), or the recombinant Rab GDP-dissociation inhibitor,
Gdi1 (10 M (31)). Large scale fusion reactions contained the same
proportions of all reagents as above.
Affinity Purification—All experiments were with protease-deficient
vacuoles (BJ3505 background) unless written otherwise. After incuba-
tion in a large scale fusion reaction (where indicated in the figures),
vacuoles were diluted to 1.5 ml with PSK buffer (10 mM PIPES/KOH,
pH 6.8, 200 mM sorbitol, 150 mM KCl), pelleted (5 min, 12,000 g, 4 °C),
washed once with 500 l of PSK buffer, and pelleted again. Membranes
were detergent-solubilized in 1 ml of lysis buffer composed of 0.5%
Triton X-100, 20 mM HEPES/KOH, pH 7.4, and 150 mM KCl (see below
for exceptions). The following protease inhibitors were used: 1 prote-
ase inhibitor mixture, 1 mM phenylmethylsulfonyl fluoride, 10 g/ml
2-macroglobulin (Roche Applied Science). Lysis was for 10 min on a
nutator at 4 °C. A fraction of the cleared extracts (10 min, 20,000  g,
4 °C) was removed and trichloroacetic acid/acetone-precipitated. The
remaining detergent extract was incubated with the appropriate affin-
ity matrix overnight on a nutator at 4 °C, and beads were washed in
lysis buffer containing decreasing amounts of detergent (0.5%, 0.1%,
0.025% Triton X-100) before elution.
For Fig. 3B, vacuoles were solubilized in lysis buffer containing 0.5%
Triton X-100, 20 mM PIPES/KOH, pH 6.8, and 150 mM KCl; in Fig. 3C,
solubilization buffer was 0.1% Triton X-100, 20 mM HEPES/KOH pH
7.4, and 150 mM NaCl. Anti-GFP, anti-Sec17 or anti-Vti1 antibodies
(0.1–1 l) were cross-linked to protein A-Sepharose (Amersham Bio-
sciences), and proteins were eluted with 0.1 mM glycine, pH 2.5, and
0.025% Triton X-100 and trichloroacetic acid/acetone-precipitated.
Vacuolar trans-SNARE complexes were analyzed (Fig. 4D) by im-
munoprecipitation of Nyv1-HA with anti-HA antibodies (0.1–1 l)
bound to protein G-Sepharose (10 l; Amersham Biosciences); elution
was by boiling in SDS sample buffer containing 2-mercaptoethanol.
For tandem isolation of trans-SNARE complexes (Fig. 4E), fusion
reactions were diluted into 5 ml of PSK buffer, and vacuoles were
collected, resuspended in 1 ml of PSK buffer, and isolated again prior
to detergent lysis. Vacuole extracts were incubated for 2 h with
glutathione-Sepharose 4B (15–40 l; Amersham Biosciences), and
bound proteins were eluted with 1.5 ml of elution buffer (50 mM
HEPES/KOH, pH 7.4, 150 mM KCl, 0.1% Triton X-100, 1 mM phen-
ylmethylsulfonyl fluoride, 20 mM reduced GSH). Eluates were then
incubated with protein G-Sepharose/anti-HA antibody overnight at
4 °C. Beads were washed twice for 10 min with lysis buffer containing
0.5% and then 0.1% Triton X-100 and then for 10 min with lysis buffer
containing 300 mM KCl and 0.025% Triton X-100. Proteins were
eluted by boiling in reducing sample buffer.
For size analysis of SNARE complexes (Fig. 4F), vacuole detergent
extracts were centrifuged on continuous glycerol density gradients (10–
30%, 18 h, 250,000 g, 4 °C, SW40 rotor). 1-ml fractions were collected,
incubated with GSH-Sepharose overnight on a nutator at 4 °C, and
TABLE I
S. cerevisiae strains used in this study
Strain Genotype Reference
CUY001 BJ3505: MATa pep4::HIS3 prb1-1.6R HIS3 lys 2–208 trp1-101 ura3–52 gal2 can 31
CUY002 DKY6281: MATa leu2–3 leu2–112 ura3–52 his3-delta200 trp 1-101 lys 2–801 suc 2-9 pho8::TRP1 31
CUY009 CUY001; nyv1::HIS3 25
CUY010 CUY001; vam3::TRP1 25
CUY011 CUY002; nyv1::HIS3 25
CUY012 CUY002; vam3::TRP1 25
CUY024 CUY001; vam7::TRP1 36
CUY297 CUY001; NYV1::6xHA-TRP1 This study
CUY333 CUY010; pRS406-NOP1pr-GST-VAM3 This study
CUY334 CUY012; pRS406-NOP1pr-GST-VAM3 This study
CUY1250 CUY002; ykt6; pRS423-Ykt6pr-GFPintYkt6 This study
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washed and eluted by boiling in SDS sample buffer. Proteins were
analyzed by 12% SDS-PAGE and Western blotting (see figure legends
for methods not discussed under “Experimental Procedures”).
RESULTS
Vac8 Palmitoylation on Isolated Vacuoles Does Not Require
Exogenous ATP and Is Restricted to a Narrow Time Window
during Vacuole Fusion—On isolated yeast vacuoles, Vac8 be-
comes palmitoylated in a reaction parallel to the Sec18/17-
and ATP-dependent priming reaction (14). Vac8 palmitoyla-
tion is sensitive to antibodies against Sec18 but is insensitive
to Sec17 antibodies (14). Since Sec17 is required for Sec18 to
hydrolyze ATP (32), we asked whether Vac8 acylation needs
ATP. In previous experiments, we used [3H]palmitate for
Vac8 labeling and thus had to add ATP for its activation to
[3H]Pal-CoA (8). Here, we directly added [3H]Pal-CoA to
vacuoles and analyzed the kinetics and ATP dependence of
Vac8 labeling by SDS-PAGE and fluorography. Surprisingly,
Vac8 acylation was more efficient in the absence of ATP (Fig.
1A), even though ATP-dependent priming and fusion were
inhibited (Fig. 2A, C). This shows that ATP addition is not
necessary for Vac8 acylation and, together with the Sec17
antibody data, indicates that palmitoylation is independent
of the Sec18 ATPase activity. In addition, our results show
that the palmitoylation reaction is regulated, as it occurs
within a narrow time frame; with or without ATP, maximal
palmitoylation was achieved early in the reaction (Fig. 1A)
and was restricted to this interval (Fig. 1B). The temporal
restriction of palmitoylation could be due to either a decreas-
ing availability of substrate (Vac8, Pal-CoA) or inactivation of
the palmitoylating activity. To distinguish between these
possibilities, we incubated vacuoles with or without ATP and,
FIG. 1. Restriction of palmitoylation activity. A, time course of
palmitoylation. Isolated vacuoles (see “Experimental Procedures”) were
incubated at 26 °C in fusion reaction buffer in the presence of [3H]Pal-
CoA for the indicated times. Reactions were stopped by shift to ice, and
vacuoles were re-isolated and resuspended in SDS sample buffer with-
out 2-mercaptoethanol. Palmitoylated Vac8 (palm. Vac8) was identified
by SDS-PAGE and fluorography. B, addition of Vac8-GST and [3H]Pal-
CoA to the ongoing reaction. Vacuoles were incubated at 26 °C in the
absence or presence of an ATP in fusion reaction buffer. At the indicated
time points, purified Vac8-GST and [3H]Pal-CoA were added, samples
were incubated for 30 min, and then the reaction was placed on ice.
Vacuoles were processed as described in A, to detect palmitoylated
Vac8. C, comparison of palmitoylation on vacuoles and after extraction,
as schematized in the left panel. Vacuoles were incubated at 26 °C in
fusion reaction buffer without ATP. At the indicated time points,
[3H]Pal-CoA was added, and samples were incubated for another 30
min and then processed as described in A (top right panel). A parallel
vacuole incubation was extracted prior to incubation with [3H]Pal-CoA
as described under “Experimental Procedures” (bottom right panel).
FIG. 2. Different functions of Sec18 in palmitoylation and
priming. A, EDTA blocks ATP-dependent release of Sec17 from vacu-
oles. BJ3505 vacuoles were incubated for 10 min at 26 °C in a 150-l
reaction containing cytosol, CoA, and His6-Sec18 in the presence or
absence of ATP-regenerating system and EDTA (1 mM). Vacuoles were
re-isolated, washed twice with 500 l of PSK buffer, and analyzed by
immunoblotting with anti-Sec17 antibodies. B, EDTA enhances Vac8
palmitoylation. The experiment was identical to that described in A,
except that it was twice as large and contained [3H]palmitate (150 Ci),
and if present, ATP was without the regenerating system. Palmitoyl-
ated Vac8 was identified by non-reducing SDS-PAGE and fluorography.
C, ATPase-deficient Sec18 E350Q blocks fusion but not palmitoylation.
The indicated concentrations of Sec18 E350Q were added to fusion
reactions, and fusion was determined after 90 min (see “Experimental
Procedures”). The corresponding concentrations (as in B) of Sec18
E350Q were included in palmitoylation reactions. Quantification of the
relative incorporation of radioactivity by laser densitometry shows no
significant difference in lanes 2–5. D, Sec18 E350Q inhibits ATP-de-
pendent Sec17 release. Reactions were performed as described in A.
Where indicated, 2 M Sec18 E350Q or wild type was added to the
reaction.
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at defined time points, added recombinant Vac8-GST and
[3H]Pal-CoA for an additional incubation of 10 min. When
Vac8-GST and [3H]Pal-CoA were added after 10 min, the
labeling of both endogenous and exogenous Vac8 was signif-
icantly decreased (Fig. 1B). This indicates that the palmito-
ylating activity becomes down-regulated during the incuba-
tion. We previously showed that this activity can be
recovered from detergent-solubilized vacuoles (14, 24). In
contrast to our observations using intact vacuoles (Fig. 1A,
B), these extracts do not lose their ability to mediate Vac8
acylation over time (24). We therefore asked whether we
could use detergent extraction to rescue the ability of Vac8 to
be palmitoylated at a later time point. For this, we incubated
vacuoles for 0 and 15 min at 26 °C and then either labeled
them directly with [3H]Pal-CoA (Fig. 1C, top right panel) or
first solubilized the vacuoles with detergent and then added
[3H]Pal-CoA (Fig. 1C, bottom right panel). As expected, intact
vacuoles lost their ability to acylate Vac8 after 15 min. In
contrast, Vac8 was efficiently labeled from extracts prepared
at either time point. The fact that temporal control of Vac8
acylation is removed by extraction indicated to us that this
activity is regulated by structural rearrangements on the
vacuole. The task was then to find out more about the nature
of this vacuole-specific control mechanism. We previously
demonstrated that antibodies to Sec18 inhibit Vac8 acylation
on isolated vacuoles (8), whereas Sec18 is not involved in
acylation after detergent extraction (14). This suggests Sec18
as a potential regulator of spatiotemporally controlled Vac8
acylation. Furthermore, Sec18, Vac8, and the SNARE Ykt6,
which we identified as responsible for Vac8 acylation, are
found in association with the cis-SNARE complex (24), sug-
gesting that a better understanding of this complex might
lend insight into the control of Vac8 acylation. Therefore, we
examined the possible involvement of Sec18 and the cis-
SNARE complex in regulating palmitoylation.
ATP Hydrolysis by Sec18 Is Not Required for Vac8 Acyla-
tion—The priming reaction of in vitro vacuole fusion (i.e. cis-
SNARE disassembly and Sec17 release) (22, 23) requires Sec17
and added ATP (22). However, Sec18-dependent acylation of
Vac8 is insensitive to anti-Sec17 antibodies (14) and does not
require the addition of ATP (Fig. 1, A and B). To directly test
whether the Sec18 function in Vac8 acylation is independent of
ATP hydrolysis, we used two established methods to inhibit the
ATPase activity of Sec18. First, we incubated vacuoles in the
presence of the divalent cation chelator EDTA, which blocks
the ability of Sec18 to disassemble SNARE complexes and the
corresponding release of Sec17 from the vacuole (Fig. 2A) (22).
Strikingly, EDTA did not inhibit Vac8 palmitoylation but,
rather, stimulated it (Fig. 2B). Stimulation by EDTA might be
due to chelation of Zn2 ions that are known to interact with
sulfhydryl groups (33), although additional experiments are
necessary to clarify this point. Importantly, this observation
suggested that the palmitoylation activity does not require, or
is even more robust without, ATP hydrolysis by Sec18. We
therefore hypothesized that a Sec18 mutant homologous to the
Drosophila melanogaster comatose mutant (Sec18 E350Q (34,
35)), which cannot hydrolyze ATP, would interfere with vacuole
fusion but not palmitoylation. Vacuole fusion is assayed by a
biochemical complementation assay that measures content
mixing (see “Experimental Procedures”). When we titrated pu-
rified Sec18 E350Q into the assay, fusion was completely pre-
vented, and indeed, palmitoylation of Vac8 was unaffected (Fig.
2C). Inhibition of fusion was due to a block in priming, because
Sec18 E350Q inhibited Sec17 release from the vacuole (Fig.
2D). The presence of Sec18 E350Q, in contrast to EDTA, did not
stimulate palmitoylation.
Positioning of the Ykt6 Protein in a Novel Complex on Vacu-
oles—We previously showed that Ykt6 is required for palmi-
toylation of Vac8 (14). This is supported by the proximity of
Vac8 and Ykt6 on vacuoles and a function of the Ykt6 longin
domain early in the fusion reaction (14). Ykt6 was found to be
associated with the vacuole cis-SNARE complex (16); however,
this complex does not seem to be homogeneous. We analyzed
cis-SNARE complexes on isolated vacuoles and found that
although GFP-tagged Ykt6 interacts with the vacuolar
Q-SNARE Vam3, it is not detectable with the second vacuolar
R-SNARE, Nyv1 (Fig. 3A). Moreover, in mutants lacking the
Q-SNARE Vam7, Nyv1 is missing from the cis-SNARE com-
plex, although it still contains the Q-SNAREs Vam3 and Vti1
(36). This is not merely a Q-SNARE complex, however, as it
also contains the R-SNARE Ykt6 (Fig. 3, B and C). These data
demonstrate that the cis-SNARE complex is more heterogene-
FIG. 3. Analysis of Ykt6 and Nyv1 complexes. A, analysis of the
Ykt6 SNARE complex. Vacuoles from a strain containing only endoge-
nous untagged Ykt6 (WT, wild type; CUY002) and a strain carrying
internally GFP-tagged Ykt6 (CYU1250) as the sole Ykt6 copy (120 g
each) were processed for anti-GFP co-immunoprecipitation (CoIP) as
described under “Experimental Procedures.” Equal amounts of vacuolar
extract (input) and flow-through (FT) (5% each) are shown. Western
blots were decorated with antibodies to Vam3, Nyv1, and Ykt6. B,
analysis of Vti1 and Sec17 complexes. Wild-type and vam7 vacuoles
(60 g each) were incubated in fusion reactions with or without ATP for
10 min at 26 °C, re-isolated, and processed as described in A. Half of the
lysate was analyzed by anti-Vti1 co-immunoprecipitation and the other
half with anti-Sec17 co-immunoprecipitation. An aliquot (2% of total)
was removed prior to loading onto beads. Western blots were decorated
with antibodies against Ykt6 and Vti1 or Sec17 as indicated. C, because
the amounts of Nyv1 and Sec17 are reduced on vam7 vacuoles, the
anti-Sec17 co-immunoprecipitation in B was repeated with normalized
protein amounts; 10% of the lysate was removed prior to loading on
beads, and Western blots were decorated with antibodies against Nyv1
and Ykt6.
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ous than previously appreciated. Since priming is not required
for Ykt6-mediated palmitoylation of Vac8 (Figs. 1 and 2) and
the cis-SNARE complex appears to be heterogeneous, we hy-
pothesized that the cis-SNARE complex present on isolated
vacuoles provides R-SNAREs for two pathways: 1) Ykt6, with
the help of Sec18 in a function independent of priming, medi-
ates Vac8 palmitoylation; 2) Nyv1, following Sec18/17-depend-
ent priming, enters into the trans-SNARE complexes that drive
homotypic vacuole fusion.
To determine the involvement of vacuolar R-SNAREs in the
transition from cis- to trans-SNARE complexes, we decided to
devise a new assay to compare these two complexes (Fig. 4).
FIG. 4. Analysis of the Nyv1-containing trans-SNARE complexes. A, vacuole localization of Nyv1-HA (N-HA) and GST-Vam3 (G-V3).
Vacuoles (6 g) from the respective strains were lysed in SDS sample buffer, and SNAREs were identified by Western blotting with antibodies to
Nyv1, Vam3, and Vti1; v3, vam3; wt, wild type (parent strain). B, in vivo analysis. Vacuoles in the indicated BJ3505 strains (see Table I) were
analyzed by pulse chase with FM4-64 (46) and fluorescence or phase contrast microscopy using a Zeiss Axiovert 35 fluorescence microscope. C,
functionality of tagged SNAREs in vacuole fusion. Vacuoles from the indicated strains were fused in standard fusion reactions (see “Experimental
Procedures”) for 60–90 min with ATP, with the addition of cytosol or recombinant Sec18p (ratio of tag to wild-type fusion was invariant). In each
experiment, fusion from a reaction without ATP was subtracted and fusion was compared with wild type (set to 100%; average wild-type units 
2.6). The graph represents values averaged from multiple experiments. Error bars are standard deviations among several independent experi-
ments; n  nyv1. D, specificity of trans-complex formation confirmed by inhibitors. Vacuoles were incubated in the presence of cytosol with
either no ATP, ATP alone, or ATP with the late-stage fusion inhibitor MCLR or the tethering inhibitor Gdi1, as described under “Experimental
Procedures.” The graph shows in vitro fusion between BJ Nyv1-HA/DKY GST-Vam3 vacuoles (3 g each). Control reactions with ATP/no inhibitor
were set to 100%. Error bars are standard deviations among n experiments: ATP  10; ATP (no inhibitor control)  10; MCLR (10 M)  7;
recombinant Gdi1 (9 M)  2. In the Western, large scale fusion reactions containing 40 g each of Nyv1-HA and GST-Vam3 (both BJ3505) and
the reaction components described above were incubated for 30 min at 26 °C. Vacuoles were re-isolated and detergent-solubilized, and 2% of them
were removed and trichloroacetic acid-precipitated (the ATP sample is shown), and protein complexes were analyzed by anti-HA co-immuno-
precipitation (co-IP) (see “Experimental Procedures” for details). Lanes are from a single representative gel but are arranged in the figure as
indicated by white spaces. Blots were decorated with anti-Vam3 followed by anti-HA antibodies. E, affinity isolation of the trans-SNARE complex.
A schematic diagram of the assay is shown. Fusion reactions (2.25 ml) containing 225 g each of GST-Vam3 and Nyv1-HA vacuoles were incubated
with 10 M MCLR / ATP for 30 min. Lysis of vacuoles and sequential isolation of complexes by GSH pull-down, and anti-HA immunoprecipi-
tation was as described under “Experimental Procedures.” Proteins were analyzed by SDS-PAGE and Western blotting with the indicated
antibodies. F, sizing of wild-type cis- and trans-SNARE complexes. Vacuoles were treated as described in E through the solubilization step, and
extracts were fractionated by ultracentrifugation on 10–30% continuous glycerol density gradients (18 h, 250,000  g, 4 °C, SW40 rotor; 1  top
of gradient) and then subjected to GSH pull-downs (see “Experimental Procedures”). Complexes were analyzed by Western blotting with the
indicated antibodies. Sizes were determined by a parallel marker-mixture gradient (Amersham Biosciences). The sizes (in kDa) of marker proteins
and their corresponding gradient fractions are indicated.
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The existing assay of trans-SNARE pairing is based on the
establishment of Vam3/Nyv1 interactions, in trans, between
nyv1 and vam3 vacuoles (37). Vam3 is the “heavy chain” of
the vacuolar Q-SNARE complex containing Vam3, Vam7, and
Vti1 and is required for fusion of vacuoles (25, 37) and lipo-
somes (38); in both assays, Nyv1 was identified as the valid
R-SNARE (25, 37, 38). Because SNARE mutants were used,
however, this assay precludes a comparison of trans-SNAREs
with cis-SNAREs and permits analysis of only binary interac-
tions between Vam3 and Nyv1; complete trans-SNARE com-
plexes between biological membranes have been uncharacter-
ized until now.
For our new assay, we tagged Vam3 in one strain and Nyv1
in the other, so that a mixture of vacuoles purified from these
strains would form doubly tagged trans-SNARE complexes.
Vam3 was tagged at its N terminus with GST, and Nyv1 was
C-terminally 6xHA-tagged. Both proteins behave like their un-
tagged counterparts, based on the criteria of vacuole localiza-
tion (Fig. 4A), vacuole morphology (Fig. 4B), and in vitro vac-
uole fusion (Fig. 4C), indicating that neither tag interferes with
SNARE function. Thus, our new assay uses vacuoles with wild-
type characteristics.
Nyv1-HA/GST-Vam3 SNARE pairs are detected when vacu-
oles carrying the respective tags are incubated together under
normal fusion conditions, solubilized, and subject to affinity
precipitation with anti-HA antibodies or GSH beads (Fig. 4D
and data not shown). Complexes are prevented when priming
or tethering are blocked by withholding, respectively, ATP or
Gdi1 inactivation of the Rab GTPase Ypt7 (39), showing
that they form in line with the fusion reaction and prior to
solubilization. Authentic trans-SNARE pairs, i.e. formed in
trans prior to fusion rather than as a result of fusion, are
observed when vacuoles are incubated with the late-stage fu-
sion inhibitors MCLR (40, 41), 1,2-bis(2-aminophenoxy)ethane-
N,N,N,N-tetraacetic acid (BAPTA) (7, 42), or GTPS (40, 43)
(Fig. 4D and data not shown).
Using our newly established assay, we determined the com-
position of trans-SNARE complexes and compared it with the
vacuolar cis-complex. To detect complete trans-SNARE com-
plexes rather than binary SNARE interactions, we took advan-
tage of the reversible association of GST-Vam3 with GSH
beads. SNARE complexes were enriched on GSH beads, re-
leased by the addition of reduced glutathione to maintain com-
plex integrity, and re-isolated with HA antibodies, so that only
those proteins that stably associate with trans-interacting
GST-Vam3 and Nyv1-HA were recovered (Fig. 4E). Vti1 and
Vam7 co-purified with the trans-SNARE complex, whereas
Sec17 and Ykt6 are absent (Fig. 4E and data not shown).
In order to confirm the absence of Ykt6 from Nyv1-contain-
ing trans-SNARE complexes, we determined the size of com-
plexes containing trans-interacting GST-Vam3 and Nyv1-HA.
Vacuoles were incubated with ATP and a fusion inhibitor (as
described above), to allow for trans-SNARE formation, and
then detergent-solubilized. The extract was then centrifuged
through a 10–30% glycerol gradient, and complexes between
Nyv1-HA and GST-Vam3 were analyzed by GSH pull-downs of
the individual fractions. As shown in Fig. 4F, Nyv1-HA/GST-
Vam3 complexes were isolated from fractions corresponding to
a size of 10 S. This suggests that Vam3, Vam7, Vti1, and Nyv1
form the trans-SNARE complex core, in keeping with the re-
quirement of these four SNAREs for liposome fusion (38). Ykt6
was not found in the Nyv1-containing trans-SNARE complex
FIG. 4—continued
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(Fig. 4F, right). This is consistent with our observation that
vacuolar cis-SNARE complexes do not contain both Nyv1 and
Ykt6 (Fig. 3A). Multimerization of cis-SNARE complexes, or
the segregation of higher order complexes into different mem-
brane domains, might have allowed previous co-purification of
Nyv1 and Ykt6 under less stringent conditions (16).
We suggest, based on the current data, that there are differ-
ent vacuolar subcomplexes containing one or the other core
R-SNARE. Nyv1 appears to form classical, four-helix bundle
SNARE complexes, whereas Ykt6 has a unique function with
Sec18 in coordinating palmitoylation of the fusion factor Vac8.
DISCUSSION
We previously reported that Vac8 is palmitoylated during an
early stage of vacuole fusion (8). This reaction is mediated by
the SNARE Ykt6 (14). Vac8 association with vacuolar SNAREs
and inhibition of palmitoylation by Sec18 antibodies suggested
that priming might be required for palmitoylation. However,
since Sec17 antibodies did not inhibit Vac8 palmitoylation, we
suspected that Sec18 has a novel role in the palmitoylation
reaction (14). Here, we have shown that this potential role of
Sec18 is indeed independent of cis-SNARE disassembly, as it
does not require ATP hydrolysis. EDTA and an ATP hydrolysis-
defective Sec18 protein (E350Q) both blocked fusion but did not
inhibit palmitoylation. One possible explanation for this is that
Sec18 is not directly involved in the regulation of Vac8 palmi-
toylation and that the inhibition by anti-Sec18 is steric. This
would be intriguing because other antibodies that recognize the
cis-complex do not have this effect, and it might give insights
into the architecture of the palmitoylation complex. Alterna-
tively, Sec18 could be directly implicated in promoting Vac8
acylation in an ATP-independent manner. This would occur in
parallel or prior to the ATP- and Sec17-dependent function of
Sec18 in cis-SNARE complex disassembly (14). As neither
Sec18-dependence (14) nor temporal regulation of the palmi-
toylating activity was observed for vacuolar extracts (Fig. 1),
we speculate that Sec18 is implicated in rearrangements of
vacuole protein complexes that link palmitoylation to the rest
of the fusion reaction. Early studies on vacuole fusion revealed
a salt- and temperature-dependent “stage I” that occurs inde-
pendent of and prior to the ATP-dependent priming stage (44).
Vac8 palmitoylation requires salt and incubation at a physio-
logical temperature (24) but does not need ATP; perhaps, then,
Vac8 palmitoylation corresponds to stage I, which may in-
volved Sec18 in an unconventional role. This would raise the
possibility that completion of stage I is the ATP- and priming-
independent signal that terminates Vac8 palmitoylation on
vacuoles.
How do we define the cis-complex, with which Ykt6, Sec18, and
Vac8 are associated, that is responsible for the regulation of
palmitoylation? A previous study reported that Ykt6, under mild
purification conditions, is in a complex with multiple vacuolar
SNAREs, including the R-SNARE Nyv1 (16). Our present anal-
ysis of SNARE complexes on wild-type and mutant membranes
(Figs. 3 and 4), however, reveals a different picture. We found
that SNARE complexes isolated from vacuoles contain either
Nyv1 or Ykt6, consistent with the findings from studies with
liposomes that Nyv1 and Ykt6 are mutually exclusive in SNARE
complexes (38). We conclude that the previous stoichiometric
co-isolation of Ykt6 and Nyv1 was most likely a result of the
lateral association of distinct complexes and that the vacuolar
cis-complex is more heterogeneous than thus far appreciated.
If Nyv1 forms the trans-SNARE complexes that drive homo-
typic vacuole fusion, why does vacuole fusion require an addi-
tional R-SNARE complex? We previously showed that vacuole
fusion first gains resistance to Ykt6 antibodies and only later
(at docking) does it become resistant to antibodies against the
other vacuolar SNAREs. Ykt6 itself is a palmitoylated protein,
both in humans (20) and in yeast (47). We also recently found
that Ykt6 undergoes priming-dependent release from vacuoles,
by a mechanism that might require its depalmitoylation. Thus,
it appears that during homotypic vacuole fusion, Ykt6 does not
behave as a classical SNARE. Instead, it might take advantage
of its association with vacuolar SNAREs (indeed, it is required
as a SNARE for traffic to the vacuole (17, 45)) to participate in
other fusion subreactions such as Vac8 palmitoylation.
We are beginning to understand how palmitoylation at the
vacuole is controlled. We propose the following working model
for Ykt6-mediated palmitoylation of Vac8. On isolated vacu-
oles, Vac8 is associated with a cis-SNARE subcomplex that
contains Ykt6. Ykt6, with the help of Sec18, transfers its palmi-
tate to Vac8. This is a priming-independent reaction (parallel
or prior to priming) that, nevertheless, is under strict spatio-
temporal control. Ykt6 remains tightly associated with the
vacuole because it is part of a cis-SNARE complex four-helix
bundle. Following priming, Ykt6 dissociates from its SNARE
partners and, having lost its stable lipid anchor, falls off the
membrane.
In conclusion, we have found that Vac8 palmitoylation must
be limited to a specific window of vacuole fusion, which is
controlled by a specialized, Ykt6-containing cis-SNARE sub-
complex. A detailed analysis of this Ykt6 complex will be an
important task for future research.
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